Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances

Cartesian Therapeutics (RNAC) Preferred Shares Issued (2023 - 2024)

Cartesian Therapeutics (RNAC) has disclosed Preferred Shares Issued for 2 consecutive years, with $40.0 million as the latest value for Q1 2024.

For Q1 2024, Preferred Shares Issued changed N/A year-over-year to $40.0 million; the TTM value through Dec 2024 reached $40.0 million, up 97.53%, while the annual FY2024 figure was $40.0 million, 97.53% up from the prior year.
Preferred Shares Issued hit $40.0 million in Q1 2024 for Cartesian Therapeutics, up from $20.2 million in the prior quarter.
Across five years, Preferred Shares Issued topped out at $40.0 million in Q1 2024 and bottomed at $20.2 million in Q4 2023.